← Patent-cliff monitor small molecule ELIQUIS SPRINKLE APIXABAN
Loss of exclusivity May 2041 latest FDA-listed patent expiry
Company BRISTOL MYERS SQUIBB CO
Drug detail Brand name ELIQUIS SPRINKLE Active ingredient APIXABAN Strength 0.15MG Dosage form FOR SUSPENSION Route ORAL Modality Small molecule FDA approval April 2025 Marketing status RX
Listed patents Patent Expires Type 11896586*PED May 2041 — 11896586 November 2040 product 6967208*PED May 2027 — 6967208 November 2026 substance, product
Regulatory exclusivity Code Expires PED October 2028 NP April 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.